Kinasih Prayuni, Kinasih
Departemen Farmakologi, Fakultas Kedokteran, Universitas YARSI Jakarta,

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Pengembangan Metode In-House HLA-Typing Gen HLA Kelas I (HLA A, HLA B, dan HLA C) Menggunakan Next Generation Sequencing Illumina MiSeq Yuliwulandari, Rika; Prayuni, Kinasih; Kenconoviyati, Kenconoviyati; Susilowati, R. W.; M. Sofro, Abdul Salam
Majalah Kedokteran Bandung Vol 47, No 3 (2015)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Human leucocyte antigen (HLA) adalah protein penyaji antigen yang lokus genetiknya berada di kromosom 6p21 dengan ukuran sebesar 3,8 Mb dan berasosiasi dengan lebih dari 100 penyakit berbeda yang  kebanyakan merupakan penyakit autoimun. Proses HLA-typing menggunakan sekuensing Sanger masih memberikan ambiguitas terhadap determinasi alel, low-throughput, dan membutuhkan biaya besar untuk sampel dalam jumlah besar. Next generation sequencing (NGS) menjadi metode yang dapat mengatasi kelemahan sekuensing Sanger. MiSeq dari Illumina merupakan salah satu NGS yang digunakan untuk HLA-typing. MiSeq memberikan kemudahan preparasi dan fleksibilitas metode yang dapat dikembangkan sesuai dengan kebutuhan laboratorium penelitian. Penelitian dilakukan di Laboratorium Molekular Genetik, Laboratorium Terpadu Universitas YARSI pada empat orang mahasiswa Fakultas Kedokteran Universitas YARSI etnik Melayu selama periode Mei–Desember 2014. Hasil menunjukkan terdapat total 546 SNP heterozygous, 888 SNP homozygous, 25 insersi, dan 23 delesi dari keseluruhan 11 sampel amplikon dengan coverage 2.106,536x dengan 2x25 siklus pembacaan. Optimasi metode HLA-typing dapat dikatakan berhasil dengan mengombinasikan long-range PCR dan pemilihan ukuran library 300–600 bp. [MKB. 2015;47(3):152–159]Kata kunci: HLA Kelas I, MiSeq, next generation sequencingDevelopment of Class I HLA Gene In-House HLA-Typing Methods (HLA A, HLA B, and HLA C) using Next Generation Sequencing Illumina MiSeqAbstractHuman leukocyte antigen (HLA) is a 3.8 Mb protein presenting antigen whose genetic locus is located in chromosome 6p21 area and have association with more than 100 different diseases that are mostly autoimmune diseases. HLA-typing process using Sanger sequencing still  creates ambiguity in the  determination of  alleles, low-throughput, and costly as it requires a large quantity of sample. Next generation sequencing (NGS) is a method that can overcome the drawbacks of Sanger sequencing. MiSeq Illumina is one of the NGSs that are used for HLA-typing. This study was conducted at the Laboratory of Molecular, Universitas YARSI in a period from May to December 2014. MiSeq provides convenience and flexibility in the preparation methods that can be developed according to the needs of the research laboratory. The results showed that there were a total of 546 SNPs that were heterozygous, 888homozygous SNP, 25 insertions and 23 deletions from the overall 11 amplicon samples with an average coverage with 2x25 read length of  2,106,536x. Our protocol generates good result as we combined long PCR amplicon and size selection method to 300–600 bp fragment.  [MKB. 2015;47(3):152–159]Key words: HLA Class I, MiSeq, next generation sequencing DOI: 10.15395/mkb.v47n3.389
THE RISK FACTORS FOR DRUG INDUCED HEPATITIS IN PULMONARY TUBERCULOSIS PATIENTS IN DR. SOETOMO HOSPITAL Soedarsono Soedarsono; Sari Mandayani; Kinasih Prayuni; Rika Yuliwulandari
Indonesian Journal of Tropical and Infectious Disease Vol. 7 No. 3 (2018)
Publisher : Institute of Topical Disease Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (457.097 KB) | DOI: 10.20473/ijtid.v7i3.8689

Abstract

Tuberculosis (TB) is still a major public health problem in Indonesia. Anti-tuberculosis drug-induced hepatotoxicity (DIH) is common side effect leading to changes in treatment regimens, and the less effective second-line treatments. Several risk factors such as age, sex, body mass index (BMI) and acetylization status for hepatotoxicity were suggested in previous studies but in the fact, those are often not related to DIH incidence after receiving standard TB treatment regimen. The aim of this study was to asses the role of risk factors in the DIH incidence in pulmonary TB patients receiving standard TB treatment regimen in Dr. Soetomo Hospital, Surabaya. Study design was analytic observational with case control. The subjects were 30 TB DIH patients and 31 TB non-DIH patients receiving standard national TB program therapy. DIH severity was divided based on International DIH Expert Working Group. Demographic data and BMI status were taken from medical records. The age classification are ≥35 years old and <35 years old as one of the risk factors studied. DNA sequencing was used to assess single-nucleotide polymorphisms in NAT2 coding region to evaluate acetylator status from blood samples. The risk factors were evaluated using chi-square test and Mantel-Haenszel test. Significant association between low BMI and DIH in general was identified (OR=3.017; 95% CI=1.029-8.845) and more significant association between low BMI and moderate DIH (OR=15.833; 95% CI=1.792-139.922). Age, sex, and acetylization status has no significant correlation with DIH incidence in general. Significant association between slow acetylator phenotype and incidence of moderate DIH was identified (OR=7.125; 95% CI= 1.309-38.711). In conclusion, some risk factors were correlated to DIH incidence in pulmonary TB patientsreceiving standart TB treatment regimen.